Literature DB >> 19735531

A vertical VAS is a valid instrument for monitoring headache pain intensity.

C Lundqvist1, J S Benth, R B Grande, K Aaseth, M B Russell.   

Abstract

Visual analogue scales (VAS) are well-validated instruments for assessing pain intensity, but have an impractical format. The aim of the study was to validate a vertical against a horizontal VAS for pain intensity registration. Out-patients with headache or non-headache pain were included. Participants completed a horizontal and a vertical VAS. Both were completed twice for test-retest. Headache was diagnosed according to the International Classification of Headache Disorders, 2nd edition. The results on vertical and horizontal VAS did not differ significantly in the different headache or chronic pain groups. For test-retest evaluation, effect sizes and Cohen's delta values were < 0.029 with < 1.5% change from test to retest (P < 0.01). Correlation coefficients were > 0.95. Bland-Altman analysis showed good agreement between vertical and horizontal scores with correlation coefficients > 0.84. A vertical VAS is equally valid as a horizontal VAS for registration of pain intensity in headache and non-headache patients.

Entities:  

Mesh:

Year:  2009        PMID: 19735531     DOI: 10.1111/j.1468-2982.2008.01833.x

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  17 in total

1.  Cigarette smoking and self-assessed upper airway health.

Authors:  Thomas Kjærgaard; Milada Cvancarova; Sverre K Steinsvåg
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-05-29       Impact factor: 2.503

2.  [Assessment of pruritus - current standards and implications for clinical practice : consensus paper of the Action Group Pruritus Parameter of the International Working Group on Pruritus Research (AGP)].

Authors:  S Ständer; C Blome; B Breil; P Bruland; U Darsow; M Dugas; A Evers; F Fritz; M Metz; N Q Phan; U Raap; A Reich; G Schneider; S Steinke; J Szepietowski; E Weisshaar; M Augustin
Journal:  Hautarzt       Date:  2012-07       Impact factor: 0.751

Review 3.  Manual therapies for migraine: a systematic review.

Authors:  Aleksander Chaibi; Peter J Tuchin; Michael Bjørn Russell
Journal:  J Headache Pain       Date:  2011-02-05       Impact factor: 7.277

4.  Exercise as migraine prophylaxis: a randomized study using relaxation and topiramate as controls.

Authors:  Emma Varkey; Asa Cider; Jane Carlsson; Mattias Linde
Journal:  Cephalalgia       Date:  2011-09-02       Impact factor: 6.292

5.  Headache prevalence and its characterization amongst hospital workers in Enugu, South East Nigeria.

Authors:  Ikenna Onwuekwe; Tonia Onyeka; Emmanuel Aguwa; Birinus Ezeala-Adikaibe; Oluchi Ekenze; Elias Onuora
Journal:  Head Face Med       Date:  2014-11-25       Impact factor: 2.151

6.  Is it possible to objectify the visual pain scale?

Authors:  Mehmet Ergin; Abdullah Sadik Girisgin; Zerrin Defne Dundar; Goknil Saniye Calik; Izzetin Ertas; Mehmet Taskin Egici
Journal:  Pak J Med Sci       Date:  2015 Nov-Dec       Impact factor: 1.088

7.  Study protocol: brief intervention for medication overuse headache--a double-blinded cluster randomised parallel controlled trial in primary care.

Authors:  Espen Saxhaug Kristoffersen; Jørund Straand; Jūratė Saltytė Benth; Michael Bjørn Russell; Christofer Lundqvist
Journal:  BMC Neurol       Date:  2012-08-10       Impact factor: 2.474

Review 8.  Using surveys to calculate disability-adjusted life-year.

Authors:  Wolfgang Wiedermann; Ulrich Frick
Journal:  Alcohol Res       Date:  2013

9.  Quality of Life and Economic Burden in Recessive Dystrophic Epidermolysis Bullosa.

Authors:  In Kyung Jeon; Hye Rang On; Soo-Chan Kim
Journal:  Ann Dermatol       Date:  2016-01-28       Impact factor: 1.444

10.  Chiropractic spinal manipulative therapy for migraine: a study protocol of a single-blinded placebo-controlled randomised clinical trial.

Authors:  Aleksander Chaibi; Jūratė Šaltytė Benth; Peter J Tuchin; Michael Bjørn Russell
Journal:  BMJ Open       Date:  2015-11-19       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.